Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer - PubMed (original) (raw)
. 2003 Jun 15;63(12):3403-12.
Affiliations
- PMID: 12810677
Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer
Lin Zhang et al. Cancer Res. 2003.
Abstract
Vascular remodeling in host tissues surrounding growing tumors is implicated in the successful development of tumor neovasculature. Cooperation between vascular endothelial growth factor (VEGF) and angiopoietins (Angs) is considered to be critical in this context. However, the mechanisms regulating the coordinated expression of these molecules remain, to date, elusive. In this study, we used a murine ovarian cancer angiogenesis model induced by overexpression of VEGF, as well as 52 human ovarian cancer specimens and 36 established cancer cell lines to characterize the expression and regulation of Ang-2 in the context of tumor angiogenesis. Using a combination of immunohistochemistry, laser capture microdissection and real-time quantitative reverse transcription-PCR, we showed that tumor-derived VEGF significantly up-regulated the expression of Ang-2 in host stroma endothelial cells, resulting in markedly increased Ang-2/Tie-2 mRNA copy number ratio in vivo. In vitro experiments showed that VEGF directly up-regulated Ang-2, which is mediated via VEGF receptor-2/flk-1/KDR pathway, in cultured endothelial cells through transcriptional activation rather than the enhanced mRNA stability. In human ovarian cancer, Ang-2 was primarily expressed in stroma endothelial cells and detectable in tumor cells of only 12% tumor specimens; however, it was not detected in the majority of established ovarian cancer cell lines. In addition, a significant correlation was observed between VEGF and Ang-2 mRNA expression (P < 0.01) but not between VEGF and Ang-1 or Tie-2 in human ovarian cancer specimens. In the mouse ovarian cancer model, up-regulation of Ang-2 in host stroma endothelial cells was significantly associated with pericyte loss and instability of the host vasculature surrounding the tumor. Our study suggests a novel mechanism by which tumor-derived VEGF interacts with Angs/Tie-2 system in host stroma endothelial cells and induces in a paracrine manner the remodeling of host vasculature to support angiogenesis during tumor growth.
Similar articles
- Angiopoietins and Tie-2 expression in angiogenesis and proliferation of human hepatocellular carcinoma.
Mitsuhashi N, Shimizu H, Ohtsuka M, Wakabayashi Y, Ito H, Kimura F, Yoshidome H, Kato A, Nukui Y, Miyazaki M. Mitsuhashi N, et al. Hepatology. 2003 May;37(5):1105-13. doi: 10.1053/jhep.2003.50204. Hepatology. 2003. PMID: 12717391 - Angiopoietin-2 is related to tumor angiogenesis in gastric carcinoma: possible in vivo regulation via induction of proteases.
Etoh T, Inoue H, Tanaka S, Barnard GF, Kitano S, Mori M. Etoh T, et al. Cancer Res. 2001 Mar 1;61(5):2145-53. Cancer Res. 2001. PMID: 11280779 - Angiopoietin-1 inhibits vascular permeability, angiogenesis, and growth of hepatic colon cancer tumors.
Stoeltzing O, Ahmad SA, Liu W, McCarty MF, Wey JS, Parikh AA, Fan F, Reinmuth N, Kawaguchi M, Bucana CD, Ellis LM. Stoeltzing O, et al. Cancer Res. 2003 Jun 15;63(12):3370-7. Cancer Res. 2003. PMID: 12810673 - New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF.
Holash J, Wiegand SJ, Yancopoulos GD. Holash J, et al. Oncogene. 1999 Sep 20;18(38):5356-62. doi: 10.1038/sj.onc.1203035. Oncogene. 1999. PMID: 10498889 Review. - Possible involvement of VEGF-FLT tyrosine kinase receptor system in normal and tumor angiogenesis.
Shibuya M, Seetharam L, Ishii Y, Sawano A, Gotoh N, Matsushime H, Yamaguchi S. Shibuya M, et al. Princess Takamatsu Symp. 1994;24:162-70. Princess Takamatsu Symp. 1994. PMID: 8983073 Review.
Cited by
- A novel angiopoietin-2 selective fully human antibody with potent anti-tumoral and anti-angiogenic efficacy and superior side effect profile compared to Pan-Angiopoietin-1/-2 inhibitors.
Thomas M, Kienast Y, Scheuer W, Bähner M, Kaluza K, Gassner C, Herting F, Brinkmann U, Seeber S, Kavlie A, Welschof M, Ries S, Weidner KM, Regula JT, Klein C. Thomas M, et al. PLoS One. 2013;8(2):e54923. doi: 10.1371/journal.pone.0054923. Epub 2013 Feb 6. PLoS One. 2013. PMID: 23405099 Free PMC article. - Breaking down the evidence for bevacizumab in advanced cervical cancer: past, present and future.
Rodriguez-Freixinos V, Mackay HJ. Rodriguez-Freixinos V, et al. Gynecol Oncol Res Pract. 2015 Sep 21;2:8. doi: 10.1186/s40661-015-0015-0. eCollection 2015. Gynecol Oncol Res Pract. 2015. PMID: 27231568 Free PMC article. Review. - The multiple combination of Paclitaxel, Ramucirumab and Elacridar reverses the paclitaxel-mediated resistance in gastric cancer cell lines.
Schirizzi A, Contino M, Carrieri L, Riganti C, De Leonardis G, Scavo MP, Perrone MG, Miciaccia M, Kopecka J, Refolo MG, Lotesoriere C, Depalo N, Rizzi F, Giannelli G, Messa C, D'Alessandro R. Schirizzi A, et al. Front Oncol. 2023 Feb 16;13:1129832. doi: 10.3389/fonc.2023.1129832. eCollection 2023. Front Oncol. 2023. PMID: 36874116 Free PMC article. - Absence of host-secreted protein acidic and rich in cysteine (SPARC) augments peritoneal ovarian carcinomatosis.
Said N, Motamed K. Said N, et al. Am J Pathol. 2005 Dec;167(6):1739-52. doi: 10.1016/S0002-9440(10)61255-2. Am J Pathol. 2005. PMID: 16314484 Free PMC article. - Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trial.
Ott PA, Nazzaro M, Pfaff KL, Gjini E, Felt KD, Wolff JO, Buchbinder EI, Haq R, Sullivan RJ, Lawrence DP, McDermott DF, Severgnini M, Giobbie-Hurder A, Rodig SJ, Stephen Hodi F. Ott PA, et al. J Immunother Cancer. 2021 Nov;9(11):e003318. doi: 10.1136/jitc-2021-003318. J Immunother Cancer. 2021. PMID: 34772758 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Miscellaneous